Bank of America’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $67.3M | Buy |
260,647
+69,840
| +37% | +$18.6M | ﹤0.01% | 1398 |
|
|
2025
Q4 | $47M | Buy |
190,807
+52,812
| +38% | +$11.1M | ﹤0.01% | 1602 |
|
|
2025
Q3 | $24.4M | Buy |
137,995
+16,183
| +13% | +$2.42M | ﹤0.01% | 2428 |
|
|
2025
Q2 | $16.7M | Buy |
121,812
+29,251
| +32% | +$4.3M | ﹤0.01% | 2735 |
|
|
2025
Q1 | $16.7M | Buy |
92,561
+16,762
| +22% | +$2.82M | ﹤0.01% | 2648 |
|
|
2024
Q4 | $11.9M | Sell |
75,799
-28,855
| -28% | -$5.12M | ﹤0.01% | 2774 |
|
|
2024
Q3 | $19.1M | Buy |
104,654
+11,025
| +12% | +$2.13M | ﹤0.01% | 2443 |
|
|
2024
Q2 | $17.2M | Buy |
93,629
+17,785
| +23% | +$2.99M | ﹤0.01% | 2398 |
|
|
2024
Q1 | $13.5M | Sell |
75,844
-15,349
| -17% | -$2.13M | ﹤0.01% | 2661 |
|
|
2023
Q4 | $11.3M | Buy |
91,193
+27,968
| +44% | +$3.1M | ﹤0.01% | 2754 |
|
|
2023
Q3 | $7.33M | Buy |
63,225
+20,455
| +48% | +$2.5M | ﹤0.01% | 3032 |
|
|
2023
Q2 | $5.02M | Sell |
42,770
-50,117
| -54% | -$5.12M | ﹤0.01% | 3404 |
|
|
2023
Q1 | $7.44M | Buy |
92,887
+24,844
| +37% | +$1.95M | ﹤0.01% | 3118 |
|
|
2022
Q4 | $5.39M | Buy |
68,043
+26,679
| +64% | +$1.98M | ﹤0.01% | 3327 |
|
|
2022
Q3 | $2.88M | Buy |
41,364
+2,627
| +7% | +$190K | ﹤0.01% | 3941 |
|
|
2022
Q2 | $2.54M | Sell |
38,737
-3,858
| -9% | -$240K | ﹤0.01% | 4080 |
|
|
2022
Q1 | $2.83M | Buy |
42,595
+29,386
| +222% | +$1.83M | ﹤0.01% | 4229 |
|
|
2021
Q4 | $924K | Buy |
13,209
+6,099
| +86% | +$355K | ﹤0.01% | 5366 |
|
|
2021
Q3 | $370K | Sell |
7,110
-1,100
| -13% | -$65.1K | ﹤0.01% | 5860 |
|
|
2021
Q2 | $558K | Buy |
8,210
+2,360
| +40% | +$165K | ﹤0.01% | 5333 |
|
|
2021
Q1 | $451K | Buy |
5,850
+1,321
| +29% | +$96K | ﹤0.01% | 5454 |
|
|
2020
Q4 | $272K | Sell |
4,529
-509
| -10% | -$25.4K | ﹤0.01% | 5396 |
|
|
2020
Q3 | $218K | Sell |
5,038
-632
| -11% | -$27.4K | ﹤0.01% | 5247 |
|
|
2020
Q2 | $235K | Sell |
5,670
-4,975
| -47% | -$239K | ﹤0.01% | 5129 |
|
|
2020
Q1 | $461K | Buy |
10,645
+5,412
| +103% | +$283K | ﹤0.01% | 4551 |
|
|
2019
Q4 | $290K | Sell |
5,233
-7,713
| -60% | -$378K | ﹤0.01% | 5392 |
|
|
2019
Q3 | $449K | Buy |
12,946
+7,269
| +128% | +$325K | ﹤0.01% | 5158 |
|
|
2019
Q2 | $229K | Sell |
5,677
-39
| -0.7% | -$1.27K | ﹤0.01% | 5552 |
|
|
2019
Q1 | $188K | Buy |
5,716
+5,530
| +2,973% | +$130K | ﹤0.01% | 5553 |
|
|
2018
Q4 | $3K | Buy |
186
+166
| +830% | +$3.48K | ﹤0.01% | 6840 |
|
|
2018
Q3 | $0 | Buy |
+20
| New | +$336 | ﹤0.01% | 7370 |
|
Other funds holding KRYS
ACA
VPM
VCM
SCM
RG
Bank of America's KRYS Position: Q1 2026 in Review
Bank of America increased its Krystal Biotech (KRYS) stake by 37% in Q1 2026, buying an estimated $18.6M and bringing the position to 260,647 shares worth $67.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1398.
Bank of America first reported a position in KRYS in Q3 2018 and has held it in 31 quarters since. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.
- Bank of America held 260,647 shares of Krystal Biotech worth $67.3M as of Q1 2026.
- Bank of America bought 69,840 Krystal Biotech shares in Q1 2026, an estimated $18.6M.
- Krystal Biotech made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1398 holding.
- Bank of America first reported a position in Krystal Biotech in Q3 2018 and has held it in 31 quarters since.
- 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.
Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.